专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US5693522A Anti-cancer immunotherapeutics 失效
标题翻译：抗癌免疫治疗
公开(公告)号：US5693522A
公开(公告)日：1997-12-02
申请号：US371922
申请日：1995-01-11
申请人： Sunil Chada , Mordechai Bodner , Douglas J. Jolly , Jack R. Barber , Caty E. DeJesus
发明人： Sunil Chada , Mordechai Bodner , Douglas J. Jolly , Jack R. Barber , Caty E. DeJesus
IPC分类号： C12N15/09 , A61K39/00 , A61K48/00 , A61P35/00 , C07K14/00 , C07K14/47 , C07K14/82 , C12N5/10 , C12N15/00 , C07H21/02 , C12N5/00
CPC分类号： C07K14/00 , C07K14/47 , C07K14/4746 , C07K14/82 , A61K39/00 , A61K48/00
摘要： The present invention provides a method of destroying selected tumor cells comprising administering to a warm-blooded animal a vector construct which directs the expression of at least one immunogenic, non-tumorigenic form of an altered cellular component normally associated with the selected tumor cells. Also provided are vector constructs which direct the expression of altered cellular components. Representative altered cellular components include ras.sup.*, p53.sup.*, Rb.sup.*, alter protein encoded by the Wilms' tumor gene, ubiquitin.sup.*, mucin.sup.*, DCC, APC, MCC, neu, an altered receptor, and bcr/abl. Also provided are recombinant viruses carrying a vector construct, target cells infected with the recombinant virus, and pharmaceutical compositions comprising the recombinant virus and a pharmaceutically acceptable carrier or diluent.
摘要翻译：本发明提供了破坏所选择的肿瘤细胞的方法，包括向温血动物施用指导至少一种免疫原性，非致瘤性形式的通常与所选择的肿瘤细胞相关的改变的细胞组分的载体构建体。还提供了引导改变的细胞组分的表达的载体构建体。代表性改变的细胞成分包括由Wilms肿瘤基因编码的ras *，p53 *，Rb *，改变的蛋白质，泛素*，粘蛋白*，DCC，APC，MCC，neu，改变的受体和bcr / abl。还提供携带载体构建体的重组病毒，用重组病毒感染的靶细胞，以及包含重组病毒和药学上可接受的载体或稀释剂的药物组合物。

12. 发明授权

US08034790B2 Use of MDA-7 to inhibit pathogenic infectious organisms 有权
标题翻译：使用MDA-7抑制致病性感染性生物体
公开(公告)号：US08034790B2
公开(公告)日：2011-10-11
申请号：US11001702
申请日：2004-12-01
申请人： Sunil Chada
发明人： Sunil Chada
IPC分类号： A61K38/20 , A61K48/00
CPC分类号： A61K38/20 , A61K9/0019 , A61K48/00 , C07K14/4748 , Y02A50/473 , Y02A50/475 , Y02A50/478 , Y02A50/479
摘要： Methods of suppressing or preventing an infection of a subject by a pathogen that involve administering to the subject a composition that includes a therapeutically effective amount of an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and a pharmaceutically acceptable preparation suitable for delivery to the subject, wherein the MDA-7 suppresses or prevents the infection, are disclosed. Also disclosed are methods of suppressing or preventing a viral infection of a cell, including obtaining an MDA-7 polypeptide or a nucleic acid encoding the MDA-7 polypeptide, and contacting the cell with the MDA-7 polypeptide or the nucleic acid encoding the MDA-7 polypeptide, wherein the MDA-7 suppresses or prevents infection of the cell.
摘要翻译：通过病原体抑制或预防受试者感染的方法涉及向受试者施用包含治疗有效量的MDA-7多肽或编码MDA-7多肽的核酸的组合物和适合的药学上可接受的制剂用于递送到受试者，其中MDA-7抑制或预防感染。还公开了抑制或预防细胞病毒感染的方法，包括获得MDA-7多肽或编码MDA-7多肽的核酸，并使细胞与MDA-7多肽或编码MDA的核酸接触 -7多肽，其中MDA-7抑制或预防细胞的感染。

13. 发明申请

US20080292592A1 Oncolytic Adenovirus Armed with Therapeutic Genes 审中-公开
标题翻译：具有治疗基因的溶瘤腺病毒
公开(公告)号：US20080292592A1
公开(公告)日：2008-11-27
申请号：US11568499
申请日：2005-05-02
申请人： Sunil Chada , William Wold , Lou Zumstein
发明人： Sunil Chada , William Wold , Lou Zumstein
IPC分类号： A61K35/76 , C12N7/00 , A61P31/00
CPC分类号： C12N15/86 , A61K35/761 , A61K38/00 , A61K45/06 , C07K14/47 , C07K14/4746 , C12N7/00 , C12N2710/10332 , C12N2710/10343 , C12N2830/008 , A61K2300/00
摘要： The present invention involves compositions and methods for treating preventing cancer using compositions including replication competent adenovirus. The application competent adenovirus may or may not encode a therapeutic polynucleotide.
摘要翻译：本发明涉及使用包括复制感受态腺病毒的组合物治疗预防癌症的组合物和方法。应用感受态腺病毒可以编码或不编码治疗性多核苷酸。

14. 发明申请

US20070003550A1 P53 vaccines for the treatment of cancers 有权
标题翻译： P53疫苗用于治疗癌症
公开(公告)号：US20070003550A1
公开(公告)日：2007-01-04
申请号：US11433079
申请日：2006-05-12
申请人： Scott Antonia , Dmitry Gabrilovich , Sunil Chada , Kerstin Menander
发明人： Scott Antonia , Dmitry Gabrilovich , Sunil Chada , Kerstin Menander
IPC分类号： A61K39/395
CPC分类号： A61K39/0011 , A61K45/06 , A61K47/6901 , A61K2039/5154 , A61K2039/5158 , A61K2039/53 , A61K2039/572 , A61K2039/585
摘要： The present invention relates to immunotherapy methods for treating hyperproliferative disease in humans, particularly to hyperproliferative disease that is refractory to therapy. More specifically, the invention is directed, in one embodiment, to methods for treating a subject with a hyperproliferative disease in which the expression of a self gene is upregulated in therapy-resistant hyperproliferative cells. In another embodiment, an adenoviral expression construct comprising a self gene under the control of a promoter operable in eukaryotic cells is administered to the therapy-resistant hyperproliferative cells. The present invention thus provides immunotherapies for treating therapy-resistant hyperproliferative disease by attenuating the natural immune system's CTL response against hyperproliferative cells or overexpressing mutant p53 antigens, for example.
摘要翻译：本发明涉及用于治疗人的过度增殖性疾病的免疫治疗方法，特别是治疗难治的过度增殖性疾病。更具体地，在一个实施方案中，本发明涉及治疗具有过度增殖性疾病的受试者的方法，其中自身基因的表达在耐药性过度增殖细胞中上调。在另一个实施方案中，将包含在真核细胞中可操作的启动子控制的自身基因的腺病毒表达构建体施用于耐药性过度增殖细胞。因此，本发明提供了通过减弱例如天然免疫系统对过度增殖细胞或过表达突变型p53抗原的CTL应答来治疗耐药性过度增殖性疾病的免疫疗法。

15. 发明申请

US20060052322A1 Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agent 审中-公开
标题翻译：用基因产物表达诱发剂和基因产物靶向剂联合治疗癌症
公开(公告)号：US20060052322A1
公开(公告)日：2006-03-09
申请号：US11150521
申请日：2005-06-10
申请人： Jack Roth , Guido Schumacher , Sunil Chada
发明人： Jack Roth , Guido Schumacher , Sunil Chada
IPC分类号： A61K48/00
CPC分类号： C12N15/86 , A61K38/1709 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K16/2863 , C07K2317/24 , C12N2710/10343 , A61K2300/00
摘要： The present invention concerns cancer therapy employing an expression construct that affects regulation of one or more particular nucleic acid sequences that encodes a gene product to which an agent is then targeted. In specific embodiments, the present invention relates to the use of p53 gene therapy to treat cancers in combination with Erbitux™(cetuximab). Viral and non-viral gene delivery systems are disclosed.
摘要翻译：本发明涉及使用影响一种或多种编码基因产物的特定核酸序列的调节的表达构建体的癌症疗法，所述基因产物随后被靶向。在具体实施方案中，本发明涉及p53基因治疗与Erbitux TM（西妥昔单抗）联合治疗癌症的用途。公开了病毒和非病毒基因递送系统。

16. 发明授权

US09402919B2 Vectors conditionally expressing protein 有权
标题翻译：有条件表达蛋白质的载体
公开(公告)号：US09402919B2
公开(公告)日：2016-08-02
申请号：US14001943
申请日：2012-03-02
申请人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler , Fayaz Khazi
发明人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler , Fayaz Khazi
IPC分类号： A61K48/00 , C12N15/86 , C07K14/505 , C07K14/54 , C07K14/56 , C07K14/565 , C07K14/705 , C07K14/47 , C12N15/85
CPC分类号： A61K48/0025 , A61K38/1816 , A61K38/208 , A61K38/212 , A61K48/0066 , A61K48/0075 , C07K14/4713 , C07K14/505 , C07K14/5428 , C07K14/5434 , C07K14/56 , C07K14/565 , C07K14/70567 , C07K2319/70 , C07K2319/715 , C07K2319/81 , C12N15/85 , C12N15/86 , C12N2710/10343 , C12N2750/14143 , C12N2830/002 , C12N2830/75 , C12N2830/85 , C12N2840/203
摘要： This invention relates to the field of therapeutics. Disclosed are methods of conditionally expressing erythropoietin under the control of an ecdysone receptor-based gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. The methods of the invention cause an in vivo increase in the expression of erythropoietin and an increase in the hematocrit or volume percentage of red blood cells in blood after administration of the ligand.
摘要翻译：本发明涉及治疗领域。公开了在活化配体的存在下在基于蜕皮激素受体的基因表达调节系统的控制下有条件地表达促红细胞生成素的方法和用于动物中的治疗目的的方法。本发明的方法导致体内增加促红细胞生成素的表达，并且在给予配体后血液中红血细胞的血细胞比容或体积百分数增加。

17. 发明申请

US20070231304A1 PROGNOSTIC FACTORS FOR ANTI-HYPERPROLIFERATIVE DISEASE GENE THERAPY 审中-公开
标题翻译：抗高血压病基因治疗的预防因素
公开(公告)号：US20070231304A1
公开(公告)日：2007-10-04
申请号：US11668981
申请日：2007-01-30
申请人： Robert Sobol , Sunil Chada , Louis Zumstein , Esteban Cvitkovic , Kerstin Menander
发明人： Robert Sobol , Sunil Chada , Louis Zumstein , Esteban Cvitkovic , Kerstin Menander
IPC分类号： A61K48/00 , A61K31/7105 , A61P43/00 , C12Q1/68 , A61K31/711
CPC分类号： G01N33/5011 , A61K31/00 , A61K31/7105 , A61K31/711 , A61K38/1709 , A61K48/005 , C12N15/86 , C12N2710/10343 , C12Q1/6886 , C12Q2600/106 , G01N33/502
摘要： The present invention relates to the identification of various prognostic factors that predict response in patients with hyperproliferative disease such as cancer to gene therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy. Also described are methods of treatment for Li Fraumeni syndrome, and for assessing anti-cancer gene therapy using PET scans.
摘要翻译：本发明涉及预测癌症与基因治疗等过度增殖性疾病患者反应的各种预后因素的鉴定及其在抗过度增殖性疾病基因治疗方法中的应用。还描述了Li Fraumeni综合征的治疗方法和用于使用PET扫描来评估抗癌基因治疗的方法。

18. 发明授权

US06333195B1 Crossless retroviral vectors 有权
标题翻译：无反转录病毒载体
公开(公告)号：US06333195B1
公开(公告)日：2001-12-25
申请号：US09479776
申请日：2000-01-07
申请人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
发明人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
IPC分类号： C12N15867
CPC分类号： C12N15/86 , C12N2740/13043 , C12N2740/13052
摘要： Retroviral vector constructs are described which have a 5′ LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3′ LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.
摘要翻译：描述了具有5'LTR，tRNA结合位点，包装信号，一个或多个异源序列，第二链合成起始和3'LTR的逆转录病毒载体构建体，其中载体构建体缺乏逆转录病毒gag / pol或env 编码序列。此外，描述了gag / pol和env表达盒，其中表达盒缺少共同超过8个核苷酸的连续序列。上述逆转录病毒载体构建体，gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

19. 发明授权

US6013517A Crossless retroviral vectors 失效
标题翻译：无反转录病毒载体
公开(公告)号：US6013517A
公开(公告)日：2000-01-11
申请号：US850961
申请日：1997-05-05
申请人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
发明人： James G. Respess , Nicholas J. DePolo , Sunil Chada , Sybille Sauter , Mordechai Bodner , David A. Driver
IPC分类号： C12N15/48 , C12N15/867 , C12N5/10 , C12N15/86
CPC分类号： C12N15/86 , C12N2740/13043 , C12N2740/13052
摘要： Retroviral vector constructs are described which have a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand synthesis and a 3' LTR, wherein the vector construct lacks retroviral gag/pol or env coding sequences. In addition, gag/pol, and env expression-cassettes are described wherein the expression cassettes lack a consecutive sequence of more than 8 nucleotides in common. The above-described retroviral vector constructs, gag/pol and env expression cassettes may be utilized to construct producer cell lines which preclude the formation of replication competent virus.
摘要翻译：描述了具有5'LTR，tRNA结合位点，包装信号，一个或多个异源序列，第二链合成起始和3'LTR的逆转录病毒载体构建体，其中该载体构建体缺乏逆转录病毒gag / pol或env 编码序列。此外，描述了gag / pol和env表达盒，其中表达盒缺少多于8个核苷酸的连续序列。上述逆转录病毒载体构建体，gag / pol和env表达盒可用于构建排除形成复制能力的病毒的生产细胞系。

20. 发明授权

US5736388A Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells 失效
标题翻译：能够转染真核细胞的噬菌体介导的基因转移系统
公开(公告)号：US5736388A
公开(公告)日：1998-04-07
申请号：US366522
申请日：1994-12-30
申请人： Sunil Chada , Thomas W. Dubensky, Jr.
发明人： Sunil Chada , Thomas W. Dubensky, Jr.
IPC分类号： A61K48/00 , C07K14/01 , C12N7/00 , C12N7/01 , C12N15/866 , C12N15/87 , C12N15/85 , C12N15/88
CPC分类号： C12N15/86 , C07K14/005 , C12N15/87 , C12N7/00 , A61K48/00 , C12N2795/10322 , C12N2795/10343 , C12N2800/202
摘要： Lamboid bacteriophage capable of specifically interacting with and delivering nucleic acid molecules to eukaryotic cells are disclosed. Such bacteriophage-derived gene transfer systems target one or more specific receptors on eukaryotic cells, for instance by incorporating mutant tail fiber proteins or by incorporating known ligands for specific eukaryotic receptors into lambda phage. Also disclosed are methods for identifying and producing modified bacteriophage tail fiber polypeptides capable of specifically interacting with eukaryotic transmembrane proteins. Methods of treating diseases using such gene transfer systems are also disclosed.
摘要翻译：公开了能够与真核细胞特异性相互作用并递送核酸分子的id噬噬菌体。这样的噬菌体衍生的基因转移系统靶向真核细胞上的一种或多种特异性受体，例如通过掺入突变型尾纤维蛋白或通过将已知的特异性真核受体配体掺入λ噬菌体中。还公开了用于鉴定和产生能够与真核跨膜蛋白特异性相互作用的修饰的噬菌体尾纤维多肽的方法。还公开了使用这种基因转移系统治疗疾病的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式